Silexion's SIL204 Shows Multi-Mechanism Immune Boost in KRAS Cancers
Event summary
- Silexion's SIL204 demonstrated statistically significant upregulation of FAS (CD95) and downregulation of HLA-G in KRAS-mutant pancreatic and NSCLC cell lines.
- Findings support a coordinated immune-sensitization effect across three key pathways: antigen presentation, immune-mediated apoptosis, and immune checkpoint activity.
- Silexion initiated its first clinical trial site for SIL204 at Tel Aviv Sourasky Medical Center in late July 2026.
The big picture
Silexion's data reinforces the growing trend of combining KRAS inhibition with immunotherapy to convert 'cold' tumors into responsive ones. The findings are particularly relevant for pancreatic cancer, where checkpoint inhibitors have shown limited single-agent efficacy. Silexion is now advancing SIL204 into Phase 2/3 trials, positioning itself in a competitive landscape of immuno-oncology combinations.
What we're watching
- Clinical Translation
- Whether preclinical immune-sensitization effects will translate to clinical outcomes in Phase 2/3 trials.
- Combination Strategy
- The pace at which Silexion advances SIL204 as a combination therapy with anti-PD-(L)1 checkpoint inhibitors.
- Market Differentiation
- How Silexion positions SIL204 against emerging KRAS-directed therapies in pancreatic cancer and NSCLC.
Related topics